EA201200195A1 - АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA201200195A1
EA201200195A1 EA201200195A EA201200195A EA201200195A1 EA 201200195 A1 EA201200195 A1 EA 201200195A1 EA 201200195 A EA201200195 A EA 201200195A EA 201200195 A EA201200195 A EA 201200195A EA 201200195 A1 EA201200195 A1 EA 201200195A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erbb3
binding fragments
antibodies
receptor
ektodomena
Prior art date
Application number
EA201200195A
Other languages
English (en)
Inventor
Биргит Скоеберл
Улрик Ниелсен
Майкл Фелдхаус
Original Assignee
Мерримаск Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерримаск Фармасьютикалс, Инк. filed Critical Мерримаск Фармасьютикалс, Инк.
Publication of EA201200195A1 publication Critical patent/EA201200195A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение касается нового класса антител и их антигенсвязывающих фрагментов, которые связывают внеклеточный домен рецептора ErbB3 и угнетают различные функции ErbB3. Например, описанные в настоящем документе антитела и их антигенсвязывающие фрагменты способны связываться с назначенным рецептором ErbB3 и угнетать опосредованную EGF-подобным лигандом фосфориляцию этого рецептора. Такие антитела и их антигенсвязывающие фрагменты, владеют полезной характеристикой угнетения пролиферации раковых клеток, экспрессирующих ErbB3.
EA201200195A 2009-08-21 2010-08-23 АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ EA201200195A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (1)

Publication Number Publication Date
EA201200195A1 true EA201200195A1 (ru) 2012-12-28

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200195A EA201200195A1 (ru) 2009-08-21 2010-08-23 АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ

Country Status (21)

Country Link
EP (1) EP2467164A2 (ru)
JP (1) JP5752687B2 (ru)
KR (1) KR20120059568A (ru)
CN (1) CN103002912A (ru)
AU (1) AU2010284018C1 (ru)
BR (1) BR112012003809A2 (ru)
CA (1) CA2771744A1 (ru)
CR (1) CR20120108A (ru)
DO (1) DOP2012000044A (ru)
EA (1) EA201200195A1 (ru)
EC (1) ECSP12011740A (ru)
IL (1) IL218097A0 (ru)
IN (1) IN2012DN01518A (ru)
MA (1) MA33582B1 (ru)
MX (1) MX336091B (ru)
NI (1) NI201200027A (ru)
PE (1) PE20121585A1 (ru)
SG (1) SG178509A1 (ru)
TN (1) TN2012000057A1 (ru)
WO (1) WO2011022727A2 (ru)
ZA (1) ZA201201195B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
JP5931736B2 (ja) 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Ｈｅｒ−３関連疾患を治療または予防するための物質および方法
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
DK2699602T3 (en) 2011-04-19 2017-06-06 Merrimack Pharmaceuticals Inc BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
EP2722343A4 (en) * 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-ERBB3 ANTIBODIES
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
ES2694153T3 (es) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2788377B1 (en) 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
MA49846A (fr) 2017-08-09 2020-06-17 Merus Nv Anticorps qui se lient à l'egfr et à cmet
WO2019028555A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan HER3 BINDING AGENTS AND USES THEREOF
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania

Also Published As

Publication number Publication date
IN2012DN01518A (ru) 2015-06-05
KR20120059568A (ko) 2012-06-08
ECSP12011740A (es) 2013-02-28
AU2010284018C1 (en) 2015-10-15
SG178509A1 (en) 2012-04-27
DOP2012000044A (es) 2012-06-30
MX336091B (es) 2016-01-08
MX2012002172A (es) 2012-05-29
EP2467164A2 (en) 2012-06-27
WO2011022727A2 (en) 2011-02-24
AU2010284018A1 (en) 2012-03-22
JP5752687B2 (ja) 2015-07-22
PE20121585A1 (es) 2012-11-29
AU2010284018B2 (en) 2014-06-05
IL218097A0 (en) 2012-04-30
NI201200027A (es) 2013-01-29
MA33582B1 (fr) 2012-09-01
WO2011022727A3 (en) 2013-06-27
CA2771744A1 (en) 2011-02-24
BR112012003809A2 (pt) 2019-09-24
CN103002912A (zh) 2013-03-27
JP2013506622A (ja) 2013-02-28
ZA201201195B (en) 2015-07-29
CR20120108A (es) 2012-06-05
TN2012000057A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
EA201200195A1 (ru) АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX369148B (es) Agentes de unión kir3dl2.
MX350957B (es) Moleculas de union especificas para her3 y usos de las mismas.
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
UA106070C2 (ru) Антитело, которое специфически связывается с egfr и her3
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
EA201291065A1 (ru) Антитела против vla-4
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
WO2011004028A3 (en) Tlr3 binding agents
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
IN2014CN04374A (ru)
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EA201590918A1 (ru) Антитела к bmp-6
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
NZ724395A (en) Anti-pdgf-c antibodies
MX2020002989A (es) Variantes de anticuerpo.